NRx Pharmaceuticals Stock (NASDAQ:NRXP)

Forecast Ownership Financials Chart Transcripts

Previous Close

$2.05

52W Range

$1.10 - $6.01

50D Avg

$2.28

200D Avg

$2.04

Market Cap

$34.34M

Avg Vol (3M)

$333.00K

Beta

1.41

Div Yield

NRXP Company Profile

NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Dec 04, 2017

Website

NRXP Performance

NRXP Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	-	-
Operating Income	$-18.50M	$-27.59M	$-44.40M
Net Income	$-25.13M	$-30.15M	$-35.23M
EBITDA	$-18.50M	$-30.02M	$-39.75M
Basic EPS	$-2.39	$-3.98	$-0.54
Diluted EPS	$-2.39	$-3.98	$-0.54

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts

Q4 24Mar 17, 25 | 8:30 AM

Q3 24Nov 18, 24 | 4:30 PM

Q2 24Aug 15, 24 | 4:30 PM

Peer Comparison

Ticker	Company
LGVN	Longeveron Inc.
LEXX	Lexaria Bioscience Corp.
SNTI	Senti Biosciences, Inc.
ADTX	Aditxt, Inc.
NTRB	Nutriband Inc.
VRAX	Virax Biolabs Group Limited
QNRX	Quoin Pharmaceuticals, Ltd.
RNXT	RenovoRx, Inc.
CING	Cingulate Inc.